Abstract on STA363's clinical effect on disc volume has been accepted for presentation at an important congress
Stayble Therapeutics AB ("Stayble" or the "Company") announces that the Company's scientific abstract regarding the treatment concept for herniated discs has been accepted for a poster presentation at the International Society for the Study of the Lumbar Spine (ISSLS) annual meeting in Milan, Italy, on 27-31 May 2024.
The poster presents the STA363 results on lumbar discs from the phase 2b study in degenerative disc disease (DDD) and explains why STA363 can have a treatment effect in patients with herniated discs. The result demonstrates a statistically significant reduction in both disc height and water content, which is indirectly a measure of reduced disc volume. STA363 reduces disc volume to the level of what previous studies have shown to have a pain-relieving effect in patients with herniated discs.
"ISSLS and AAPM are leading organizations where researchers and clinicians in low back diseases and pain gather. That our research is presented at these meetings, therefore, has a great impact. International experts review abstracts, and the fact that our abstract has been approved is a stamp of quality for Stayble and our research.” says Anders Lehmann, CSO.
That volume reduction of the disc is an interesting alternative to treat herniated discs was recently confirmed when the company's advisor, Dr. Douglas Beall, presented the poster Bridging the Gap Between Conservative Care and Surgery for Lumbar Disc Herniation at the American Academy of Pain Medicine's (AAPM) 40th Annual Meeting in Scottsdale USA. The poster describes current treatment options and the need for therapies that can fill the gap between conservative treatment and surgery. The poster presents five new innovations that are under clinical development, of which STA363 is one of these. The focus in the short term is prolonged pain relief and reducing disc volume. STA363 is precisely a treatment that, through a single injection, can reduce the disc volume and has the potential to permanently reduce the patient's pain.
The company's poster is titled: "Dose-dependent dehydration and disc height reduction after intradiscal STA363 (lactic acid) in patients with degenerative disc disease (DDD) indicates utility in the treatment of radiculopathy caused by lumbar disc herniation (LDH).
For more information
Andreas Gerward, CEO of Stayble Therapeutics AB
Mail: andreas.gerward@stayble.se
Phone: +46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical pharmaceutical company developing the injection treatment STA363 for chronic disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that targets the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. The treatment is aimed at patients who are not helped by physical therapy and painkillers and is a single injection that is expected to last a lifetime and requires minimal rehabilitation. After convincing data from previous pre-clinical and clinical studies (phase 1b and 2b) in degenerative disc disease, which show a volume reduction of the discs, the Company is currently conducting a phase 1b study for the treatment of herniated discs.
The company's Certified Adviser is Svensk Kapitalmarknadsgranskning AB.